ArticleHeart and vessels2016
Risk factors and serological markers of liver cirrhosis after Fontan procedure.
Article in Heart and vessels, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Clinical predictors and noninvasive imaging in Fontan-associated liver disease: A systematic review and meta-analysis.Hepatology communications · 2024Pooled it
- Liver stiffness measured by transient elastography is not predictive of mortality or adverse events in adult patients with Fontan associated liver disease.International journal of cardiology. Congenital heart disease · 2026Article
- Strain elastography for detecting advanced Fontan-associated liver disease: a retrospective study.BMC gastroenterology · 2025Article
- Impact of ursodeoxycholic acid treatment on Fontan-associated liver disease.Journal of gastroenterology · 2025Article
- Mitochondrial dysfunction is associated with the severity of liver fibrosis in patients after the Fontan operation.Journal of cellular and molecular medicine · 2024Article
- Hepatocellular carcinoma diagnosed in a patient who had Fontan operation 30 years ago: a case report.Journal of liver cancer · 2022Article
- The absence of warfarin treatment and situs inversus are associated with the occurrence of hepatocellular carcinoma after Fontan surgery.Journal of gastroenterology · 2022Article
- Screening modalities for the diagnosis of Fontan-associated liver disease: evidence from the past for future development.American journal of translational research · 2022Review
- Potential of Liver TMagnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2021Article
- From congestive hepatopathy to hepatocellular carcinoma, how can we improve patient management?JHEP reports : innovation in hepatology · 2021Review
- Incidence, Predictors, and Mortality in Patients With Liver Cancer After Fontan Operation.Journal of the American Heart Association · 2021Article
- Blood test assessment of liver ultrasound findings in patients with Fontan surgery.American journal of cardiovascular disease · 2021Article
- Fontan-associated liver disease and hepatocellular carcinoma in adults.Scientific reports · 2020Article
- Long-term results of additional pulmonary blood flow with bidirectional cavopulmonary shunt.Journal of cardiothoracic surgery · 2020Article
- Risk of Liver Cirrhosis and Hepatocellular Carcinoma after Fontan Operation: A Need for Surveillance.Cancers · 2020Article
- The Rate of Hepatic Fibrosis Progression in Patients Post-Fontan.Pediatric cardiology · 2020Article
- Forns Index is a predictor of cardiopulmonary bypass time and outcomes in Fontan conversion.Heart and vessels · 2020Article
- A case of Fontan-related hepatocellular carcinoma successfully treated with proton beam therapy.Clinical journal of gastroenterology · 2020Article
- Hepatic pathology in patients after Fontan operation: A computed tomography imaging study.Journal of the Chinese Medical Association : JCMA · 2019Article
- Hepatic Changes in the Fontan Circulation: Identification of Liver Dysfunction and an Attempt to Streamline Follow-up Screening.Pediatric cardiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver cirrhosis (LC), which may result in hepatic failure or cancer, has been reported in patients after Fontan procedure. The purpose of this study was to clarify the frequency and histological characteristics of LC, and to evaluate the risk factors and serological markers of LC with Fontan circulation. Retrospective review of contrast-enhanced CT scans (CT) of the liver was carried out in 57 patients after Fontan procedure. Patients were divided into two groups: LC group (n = 31) and no LC group (n = 26). Age at Fontan procedure, duration after Fontan procedure, catheterization data, and history of failing Fontan circulation were compared between groups. Serological data including γ-GTP and hyaluronic acid were compared. Histology of autopsy specimens was assessed when available. Duration after Fontan procedure was significantly longer in LC group than no LC group. History of failing Fontan circulation was more frequent in LC group than in no LC group. There was no correlation between type of procedure (APC/Bjork/lateral tunnel/TCPC) and LC in this series. Serum hyaluronic acid, γ-GTP, and Forns index were significantly higher in LC group. Significant risk factors for LC were duration after Fontan procedure (>20 years). In autopsy specimens, histopathological changes of LC were observed predominantly in the central venous area. LC diagnosed with CT is frequent in patients long after Fontan procedure, especially after 20 years. Hyaluronic acid and γ-GTP could be useful markers to monitor the progression of liver fibrosis in Fontan patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.